Heart failure is a common condition: according to a new study in 11 high-income countries, an estimated 1-2% of the population has heart failure. One feature of late-stage heart failure is nicotine adenine dinucleotide (NAD+), which leaves heart muscle cells unable to generate sufficient ATP to meet their energy needs. Now, investigators at The Hospital for Sick Children and the University of Toronto have shown that this metabolic dysfunction is present early in heart failure, and precedes any sign of clinical dysfunction in the heart. Read More
Scientists have identified proteins that changed in response to exercise specifically in trial participants whose blood sugar control improved after taking up an exercise regimen. Based on serum protein analysis, the investigators also developed a machine-learning algorithm that could predict whether an individual’s metabolic sensitivity would be improved by exercise. Read More
Ryne Biotechnology Inc. has been awarded a US$4 million Clinical Stage Research Program (CLIN1) grant by the California Institute for Regenerative Medicine (CIRM) to advance its lead candidate RNDP-001 through IND submission in the next 12 months. Read More
Hearing loss related to aging is mostly predicted by the degree of loss of outer hair cells. Investigators from Acousia Therapeutics GmbH have tested the novel Kv7.4 channel activator ACOU-082 in mice. Read More
Thylacine Biotherapeutics Inc. has entered into a license agreement with Columbia University for worldwide exclusive rights to develop and commercialize a novel antiviral peptide platform invented and refined at Columbia. Read More
Retinal disorders such as diabetic macular edema (DME), wet age-related macular degeneration (wAMD) or uveitic macular edema share inflammatory traits mediated by vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6), among others. Read More
Scientists from the National Institutes of Health and affiliated organizations established a novel mouse model of intraventricular extension of hemorrhage (IVH) for the purpose of measuring motor and cognitive function in acute and chronic stages of intracerebral hemorrhage, which is the most severe stroke subtype. Read More
Microbio (Shanghai) Co. Ltd. has synthesized glucagon-like peptide 1 receptor (GLP1R) agonists reported to be useful for the treatment of obesity, type 2 diabetes and nonalcoholic fatty liver disease. Read More
Micurx Pharmaceuticals Inc. has patented peptide-drug conjugates consisting of peptide targeting kidney cells covalently linked to an anti-inflammatory or immunomodulating or nephron-protective drug through a linker reported to be useful for the treatment of acute kidney injury, chronic kidney disease, chronic glomerulonephritis, diabetic nephropathy and systemic lupus erythematosus, among others. Read More
Triple-negative breast cancer (TNBC) still remains as one of the most aggressive breast cancer types among women, with high metastatic potential and ability to shift towards epithelial-mesenchymal transition (EMT). Read More
Tuojie Biotech (Shanghai) Co. Ltd. has described lysophosphatidic acid receptor 1 (LPAR1) antagonists reported to be useful for the treatment of metabolic diseases, cancer, liver diseases, respiratory, renal, neurological, cardiovascular and eye disorders, among others. Read More
Jiangsu Hengrui Medicine Co. Ltd., Shanghai Hengrui Pharmaceutical Co. Ltd., Shanghai Senhui Pharmaceutical Co. Ltd. and Shanghai Shengdi Pharmaceutical Co. Ltd. have identified antibody-drug conjugates (ADCs) comprising HER2-targeting antibody or antigen-binding fragments linked to eribulin derivatives through a cleavable linker reported to be useful for the treatment of cancer. Read More
Cathepsin L (CTS-L) is a lysosomal enzyme responsible for degrading endocytosed proteins to generate immunogenic antigens for adaptive immunities. In the current study, researchers reported data from a study that aimed to assess the potential of targeting procathepsin L (pCTS-L) as a potential therapeutic strategy against sepsis. Read More
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has presented protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer. Read More
